Bernie Sanders Just Broke With His Party Over This Trump Policy
Oh, Look Who Donated to Trump's White House Renovation Project
The Press Trips Over Themselves to Defend a Prosecutor, and Trump's Ballroom Project...
Sotomayor's Death Penalty Dissent Does More Harm Than Good
Democrats Scraping the Bottom of the Barrel for Candidates
President Trump Deploys the Ford Carrier Strike Group to the Caribbean
The Empire Strikes Back: Trump vs Venezuela, Columbia, Antifa, and Illegals
What Charlie Kirk Understood About America’s Lost Youth
Abigail Spanberger, As Governor, You’re Supposed to Make Decisions
While Washington Imports Price Controls, China Imports Our Future
Kentucky Waste Industry Mogul Promises to 'Take Out the Trash' in Washington DC
Pakistani National Sentenced to 40 Years for Smuggling Cruise Missiles, Warhead
Tennessee Attorney General Files Amicus Brief in US Supreme Court Opposing Birthright Citi...
Airline, Pilot Unions Demand That Democrats Reopen the Federal Government
Michigan Families Face SNAP Delays As Federal Shutdown Hits Day 23
Tipsheet

The FDA Just Approved This Surprising Standalone Treatment for Depression

AP Photo/Andrew Harnik, File

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray to be used alone in adults with major depressive disorder. 

Advertisement

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression. This is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.

According to CNBC, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing thoughts of suicide or harm. 

“We want to recognize that this is a medicine that treats a disease that [when] left untreated, depression is potentially fatal,” Bill Martin, J&J’s global therapeutic area head of neuroscience, said in an interview with the outlet.

Advertisement

Reportedly, about one-third of the estimated 21 million U.S. adults with major depression battle symptoms don’t respond to treatment.

“For the first time ever, we now have an option that gives patients freedom,” Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said. 

Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren’t improving their symptoms and are causing undesirable side effects.

The approval of Spravato was based on a phase four trial that showed that Spravato alone improved depressive symptoms beginning about 24 hours after treatment and lasting through at least one month. The drug first entered the US market in 2019.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement